Senate Committee Reviews Give Kids a Chance Act to Expand FDA Authority Over Pediatric Cancer Drug Studies
Stalled
No legislative action in over 90 days.
How this policy affects specific groups of people
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
No votes have been recorded for this legislation yet.
The House unanimously passed the Mikaela Naylon Give Kids A Chance Act of 2025, which expands FDA authority to require pediatric research on drug combinations and reauthorizes the priority review voucher (PRV) program to spur development for rare childhood diseases.
The Mikaela Naylon Give Kids a Chance Act combines initiatives to reauthorize the rare pediatric disease priority review voucher program and grant the FDA new authority to direct companies to study combinations of cancer drugs and therapies in pediatric trials.
Despite unanimous House passage, the Mikaela Naylon Give Kids a Chance Act faced a year-end delay in the Senate due to objections over broader healthcare package costs, stalling the reauthorization of the critical priority review voucher program for rare pediatric diseases.
Document Type
Congressional Bill
Official Title
Give Kids a Chance Act of 2025
Analysis generated by AI. Always verify with official sources.